Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Prostatic Neoplasms 237Lymphoma 176Lymphoma, Large B-Cell, Diffuse 171Precursor Cell Lymphoblastic Leukemia-Lymphoma 85Lymphoma, Follicular 77Lymphoma, Non-Hodgkin 72Burkitt Lymphoma 66Multiple Myeloma 62Leukemia 58Hodgkin Disease 45Lymphoma, Mantle-Cell 41Neoplasms 35Lymphoma, T-Cell, Peripheral 31Lymphoma, B-Cell 30Lymphoma, B-Cell, Marginal Zone 27Lymphoma, Large-Cell, Anaplastic 26Lymphoma, Large-Cell, Immunoblastic 24Neoplasm Metastasis 23Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 22Leukemia, Lymphocytic, Chronic, B-Cell 22Neoplasms, Plasma Cell 21Recurrence 19Immunoblastic Lymphadenopathy 15Dendritic Cell Sarcoma, Interdigitating 15Lymphoma, T-Cell 14Leukemia, Biphenotypic, Acute 10Waldenstrom Macroglobulinemia 9Blast Crisis 9Primary Myelofibrosis 8Myelodysplastic Syndromes 8

Interventions

Nivolumab 2prednylidene 1peginterferon alfa-2b 1dolutegravir 1deltacortene 1Zidovudine 1Vincristine 1Valproic Acid 1Tenofovir 1Specimen Handling 1Prednisone 1Pharmacogenomic Testing 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Interferon alpha-2 1Etoposide 1Doxorubicin 1Daclizumab 1Cyclophosphamide 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × HTLV-I Infections × Prednisone × Clear all
NCT04301076 2026-05-13

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡